scholarly journals Complement factor 5 (C5) p.A252T mutation is prevalent in, but not restricted to, sub-Saharan Africa: implications for the susceptibility to meningococcal disease

2017 ◽  
Vol 189 (2) ◽  
pp. 226-231 ◽  
Author(s):  
C. Franco-Jarava ◽  
D. Comas ◽  
A. Orren ◽  
M. Hernández-González ◽  
R. Colobran
2017 ◽  
Vol 89 ◽  
pp. 158-159
Author(s):  
Clara Franco-Jarava ◽  
David Comas ◽  
Ann Orren ◽  
Manuel Hernández-González ◽  
Roger Colobran

2015 ◽  
Vol 143 (11) ◽  
pp. 2259-2268 ◽  
Author(s):  
L. TELISINGHE ◽  
T. D. WAITE ◽  
M. GOBIN ◽  
O. RONVEAUX ◽  
K. FERNANDEZ ◽  
...  

SUMMARYHousehold contacts of an index case of invasive meningococcal disease (IMD) are at increased risk of acquiring disease. In revising WHO guidance on IMD in sub-Saharan Africa, a systematic review was undertaken to assess the effect of chemoprophylaxis and of vaccination in preventing subsequent cases of IMD in household contacts following an index case. A literature search for systematic reviews identified a single suitable review on chemoprophylaxis in 2004 (three studies meta-analysed). A search for primary research papers published since 2004 on chemoprophylaxis and without a date limit on vaccination was therefore undertaken. There were 2381 studies identified of which two additional studies met the inclusion criteria. The summary risk ratio for chemoprophylaxis vs. no chemoprophylaxis (four studies) in the 30-day period after a case was 0·16 [95% confidence interval (CI) 0·04-0·64, P = 0·008]; the number needed to treat to prevent one subsequent case was 200 (95% CI 111-1000). A single quasi-randomized trial assessed the role of vaccination. The risk ratio for vaccination vs. no vaccination at 30 days was 0·11 (95% CI 0·01–2·07, P = 0·14). The results support the use of chemoprophylaxis to prevent subsequent cases of IMD in household contacts of a case. Conclusions about the use of vaccination could not be drawn.


mSphere ◽  
2016 ◽  
Vol 1 (6) ◽  
Author(s):  
Adam C. Retchless ◽  
Fang Hu ◽  
Abdoul-Salam Ouédraogo ◽  
Seydou Diarra ◽  
Kristen Knipe ◽  
...  

ABSTRACT Meningococcal disease (meningitis and bloodstream infections) threatens millions of people across the meningitis belt of sub-Saharan Africa. A vaccine introduced in 2010 protects against Africa’s then-most common cause of meningococcal disease, N. meningitidis serogroup A. However, other serogroups continue to cause epidemics in the region—including serogroup W. The rapid identification of strains that have been associated with prior outbreaks can improve the assessment of outbreak risk and enable timely preparation of public health responses, including vaccination. Phylogenetic analysis of newly sequenced serogroup W strains isolated from 1994 to 2012 identified two groups of strains linked to large epidemics in Burkina Faso, one being descended from a strain that caused an outbreak during the Hajj pilgrimage in 2000. We find that applying whole-genome sequencing to meningococcal disease surveillance collections improves the discrimination among strains, even within a single nation-wide epidemic, which can be used to better understand pathogen spread. Epidemics of invasive meningococcal disease (IMD) caused by meningococcal serogroup A have been eliminated from the sub-Saharan African so-called “meningitis belt” by the meningococcal A conjugate vaccine (MACV), and yet, other serogroups continue to cause epidemics. Neisseria meningitidis serogroup W remains a major cause of disease in the region, with most isolates belonging to clonal complex 11 (CC11). Here, the genetic variation within and between epidemic-associated strains was assessed by sequencing the genomes of 92 N. meningitidis serogroup W isolates collected between 1994 and 2012 from both sporadic and epidemic IMD cases, 85 being from selected meningitis belt countries. The sequenced isolates belonged to either CC175 (n = 9) or CC11 (n = 83). The CC11 N. meningitidis serogroup W isolates belonged to a single lineage comprising four major phylogenetic subclades. Separate CC11 N. meningitidis serogroup W subclades were associated with the 2002 and 2012 Burkina Faso epidemics. The subclade associated with the 2012 epidemic included isolates found in Burkina Faso and Mali during 2011 and 2012, which descended from a strain very similar to the Hajj (Islamic pilgrimage to Mecca)-related Saudi Arabian outbreak strain from 2000. The phylogeny of isolates from 2012 reflected their geographic origin within Burkina Faso, with isolates from the Malian border region being closely related to the isolates from Mali. Evidence of ongoing evolution, international transmission, and strain replacement stresses the importance of maintaining N. meningitidis surveillance in Africa following the MACV implementation. IMPORTANCE Meningococcal disease (meningitis and bloodstream infections) threatens millions of people across the meningitis belt of sub-Saharan Africa. A vaccine introduced in 2010 protects against Africa’s then-most common cause of meningococcal disease, N. meningitidis serogroup A. However, other serogroups continue to cause epidemics in the region—including serogroup W. The rapid identification of strains that have been associated with prior outbreaks can improve the assessment of outbreak risk and enable timely preparation of public health responses, including vaccination. Phylogenetic analysis of newly sequenced serogroup W strains isolated from 1994 to 2012 identified two groups of strains linked to large epidemics in Burkina Faso, one being descended from a strain that caused an outbreak during the Hajj pilgrimage in 2000. We find that applying whole-genome sequencing to meningococcal disease surveillance collections improves the discrimination among strains, even within a single nation-wide epidemic, which can be used to better understand pathogen spread.


The Lancet ◽  
1985 ◽  
Vol 326 (8459) ◽  
pp. 829-830 ◽  
Author(s):  
B.M. Greenwood ◽  
A.K. Bradley ◽  
R.A. Wall

Vaccine ◽  
2014 ◽  
Vol 32 (23) ◽  
pp. 2688-2695 ◽  
Author(s):  
Oliver Koeberling ◽  
Emma Ispasanie ◽  
Julia Hauser ◽  
Omar Rossi ◽  
Gerd Pluschke ◽  
...  

The Lancet ◽  
1984 ◽  
Vol 323 (8390) ◽  
pp. 1339-1342 ◽  
Author(s):  
B.M. Greenwood ◽  
A.K. Bradley ◽  
I.S. Blakebrough ◽  
S. Wali ◽  
H.C. Whittle

2021 ◽  
Author(s):  
Stephen Clark ◽  
Jay Lucidarme ◽  
Ray Borrow

Meningococcal disease is caused by the Gram-negative bacterium Neisseria meningitidis (the meningococcus). It remains a significant public health issue globally causing both endemic and epidemic disease in developed and developing countries. Approximately 10% of humans harmlessly carry N. meningitidis in the oronasopharynx. On very rare occasions the bacteria may cross the epithelium and enter the blood stream causing sudden onset of sepsis and or meningitis with high complication and case fatality rates, even with appropriate antibiotic treatment. A limited number of strains cause the majority of invasive disease and, in normally healthy individuals, these practically always express a protective polysaccharide capsule on their cell surface. There are 12 capsular serogroups, of which A, B, C, W, X and Y cause the vast majority of invasive meningococcal disease worldwide. Polysaccharide-based vaccines target the capsule and so are serogroup-specific. Plain (unconjugated) polysaccharide vaccines were developed first and have been used in control of serogroup A epidemics in sub-Saharan Africa and for controlling serogroup C disease in the military and college students. Associated limitations include poor immunogenicity in young children, hyporesponsiveness with repeat doses, inability to induce immune memory and lack of an effect on carriage. Conjugated polysaccharide vaccines have none of these limitations and, most importantly, significantly reduce carriage. Therefore, large scale vaccination of cohorts with high carriage (catch-up campaigns) are highly effective in inducing herd protection. Serogroup C conjugate vaccines have been hugely successful in dramatically reducing disease in the countries that have instigated immunization programs together with appropriate catch-up campaigns. Meningococcal quadrivalent conjugate vaccines are now being implemented into schedules. With the development and introduction of a meningococcal serogroup A conjugate vaccine, serogroup A disease has disappeared from those sub-Saharan countries who have implemented campaigns. The serogroup B polysaccharide is poorly immunogenic and so broad coverage protein-based serogroup B vaccines have been developed.


2021 ◽  
Author(s):  
Stephen Clark ◽  
Jay Lucidarme ◽  
Ray Borrow

Meningococcal disease is caused by the Gram-negative bacterium Neisseria meningitidis (the meningococcus). It remains a significant public health issue globally causing both endemic and epidemic disease in developed and developing countries. Approximately 10% of humans harmlessly carry N. meningitidis in the oronasopharynx. On very rare occasions the bacteria may cross the epithelium and enter the blood stream causing sudden onset of sepsis and or meningitis with high complication and case fatality rates, even with appropriate antibiotic treatment. A limited number of strains cause the majority of invasive disease and, in normally healthy individuals, these practically always express a protective polysaccharide capsule on their cell surface. There are 12 capsular serogroups, of which A, B, C, W, X and Y cause the vast majority of invasive meningococcal disease worldwide. Polysaccharide-based vaccines target the capsule and so are serogroup-specific. Plain (unconjugated) polysaccharide vaccines were developed first and have been used in control of serogroup A epidemics in sub-Saharan Africa and for controlling serogroup C disease in the military and college students. Associated limitations include poor immunogenicity in young children, hyporesponsiveness with repeat doses, inability to induce immune memory and lack of an effect on carriage. Conjugated polysaccharide vaccines have none of these limitations and, most importantly, significantly reduce carriage. Therefore, large scale vaccination of cohorts with high carriage (catch-up campaigns) are highly effective in inducing herd protection. Serogroup C conjugate vaccines have been hugely successful in dramatically reducing disease in the countries that have instigated immunization programs together with appropriate catch-up campaigns. Meningococcal quadrivalent conjugate vaccines are now being implemented into schedules. With the development and introduction of a meningococcal serogroup A conjugate vaccine, serogroup A disease has disappeared from those sub-Saharan countries who have implemented campaigns. The serogroup B polysaccharide is poorly immunogenic and so broad coverage protein-based serogroup B vaccines have been developed.


2017 ◽  
Vol 1 (6) ◽  
pp. 533-537
Author(s):  
Lorenz von Seidlein ◽  
Borimas Hanboonkunupakarn ◽  
Podjanee Jittmala ◽  
Sasithon Pukrittayakamee

RTS,S/AS01 is the most advanced vaccine to prevent malaria. It is safe and moderately effective. A large pivotal phase III trial in over 15 000 young children in sub-Saharan Africa completed in 2014 showed that the vaccine could protect around one-third of children (aged 5–17 months) and one-fourth of infants (aged 6–12 weeks) from uncomplicated falciparum malaria. The European Medicines Agency approved licensing and programmatic roll-out of the RTSS vaccine in malaria endemic countries in sub-Saharan Africa. WHO is planning further studies in a large Malaria Vaccine Implementation Programme, in more than 400 000 young African children. With the changing malaria epidemiology in Africa resulting in older children at risk, alternative modes of employment are under evaluation, for example the use of RTS,S/AS01 in older children as part of seasonal malaria prophylaxis. Another strategy is combining mass drug administrations with mass vaccine campaigns for all age groups in regional malaria elimination campaigns. A phase II trial is ongoing to evaluate the safety and immunogenicity of the RTSS in combination with antimalarial drugs in Thailand. Such novel approaches aim to extract the maximum benefit from the well-documented, short-lasting protective efficacy of RTS,S/AS01.


Sign in / Sign up

Export Citation Format

Share Document